1.
Strausz S, Havulinna AS, Tuomi T, et al. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open. 2018;8(10):e022752. doi:10.1136/bmjopen-2018-022752.
1.
Smith G, Gerszten RE. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease. Circulation. 2017;135(17):1651-1664. doi:10.1161/CIRCULATIONAHA.116.025446.
1.
Ruiz-Canela M, Hruby A, Clish CB, Liang L, Martinez-Gonzalez MA, Hu FB. Comprehensive Metabolomic Profiling and Incident Cardiovascular Disease: A Systematic Review. J Am Heart Assoc. 2017;6(10). doi:10.1161/JAHA.117.005705.
1.
Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet. 2001;17(9):502-10.
1.
O’Sullivan JF, Morningstar JE, Yang Q, et al. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. J Clin Invest. 2017;127(12):4394-4402. doi:10.1172/JCI95995.
1.
Paynter NP, Balasubramanian R, Giulianini F, et al. Metabolic Predictors of Incident Coronary Heart Disease in Women. Circulation. 2018;137(8):841-853. doi:10.1161/CIRCULATIONAHA.117.029468.
1.
Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19(6):785-798. doi:10.1016/S1470-2045(18)30242-0.
1.
Nühs A, De Rycker M, Manthri S, et al. Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity. PLoS Negl Trop Dis. 2015;9(9):e0004094. doi:10.1371/journal.pntd.0004094.
1.
Majumder B, Baraneedharan U, Thiyagarajan S, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:6169. doi:10.1038/ncomms7169.
1.
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015;17(4):15. doi:10.1007/s11912-015-0438-0.